KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to 37.8%.

  • Vertex Pharmaceuticals' EBITDA Margin rose 25700.0% to 37.8% in Q4 2025 from the same period last year, while for Dec 2025 it was 34.77%, marking a year-over-year increase of 368900.0%. This contributed to the annual value of 34.77% for FY2025, which is 368900.0% up from last year.
  • Vertex Pharmaceuticals' EBITDA Margin amounted to 37.8% in Q4 2025, which was up 25700.0% from 38.56% recorded in Q3 2025.
  • In the past 5 years, Vertex Pharmaceuticals' EBITDA Margin registered a high of 53.15% during Q3 2021, and its lowest value of 132.85% during Q2 2024.
  • Its 5-year average for EBITDA Margin is 30.8%, with a median of 40.72% in 2024.
  • Per our database at Business Quant, Vertex Pharmaceuticals' EBITDA Margin crashed by -1740200bps in 2024 and then soared by 1716800bps in 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' EBITDA Margin (Quarter) stood at 42.35% in 2021, then rose by 6bps to 44.88% in 2022, then decreased by -13bps to 39.26% in 2023, then dropped by -10bps to 35.23% in 2024, then increased by 7bps to 37.8% in 2025.
  • Its last three reported values are 37.8% in Q4 2025, 38.56% for Q3 2025, and 38.83% during Q2 2025.